Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Orthopediatrics from a buy rating to a hold rating in a research note on Tuesday, August 13th. BTIG Research reaffirmed a buy rating and issued a $44.00 price objective on shares of Orthopediatrics in a research note on Friday, May 10th. Needham & Company LLC initiated coverage on shares of Orthopediatrics in a research note on Wednesday, June 19th. They issued a buy rating and a $53.00 price objective on the stock. Finally, ValuEngine cut shares of Orthopediatrics from a buy rating to a hold rating in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $44.25.
Orthopediatrics stock opened at $32.43 on Friday. The stock has a market cap of $463.73 million, a price-to-earnings ratio of -33.78 and a beta of 0.12. The company has a current ratio of 2.53, a quick ratio of 6.01 and a debt-to-equity ratio of 0.24. The company’s 50-day moving average price is $34.53 and its two-hundred day moving average price is $38.74. Orthopediatrics has a 52 week low of $25.11 and a 52 week high of $47.82.
Orthopediatrics (NASDAQ:KIDS) last released its earnings results on Wednesday, August 7th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.05). The company had revenue of $18.20 million for the quarter, compared to analyst estimates of $18.44 million. Orthopediatrics had a negative net margin of 15.77% and a negative return on equity of 12.92%. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.21) EPS. Research analysts expect that Orthopediatrics will post -0.82 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in KIDS. Roubaix Capital LLC acquired a new position in shares of Orthopediatrics in the 2nd quarter worth approximately $3,497,000. BlackRock Inc. grew its stake in shares of Orthopediatrics by 16.8% in the 2nd quarter. BlackRock Inc. now owns 585,555 shares of the company’s stock worth $22,837,000 after purchasing an additional 84,205 shares during the last quarter. Wasatch Advisors Inc. grew its stake in shares of Orthopediatrics by 28.2% in the 2nd quarter. Wasatch Advisors Inc. now owns 347,598 shares of the company’s stock worth $13,556,000 after purchasing an additional 76,534 shares during the last quarter. Calamos Advisors LLC acquired a new position in shares of Orthopediatrics in the 2nd quarter worth approximately $2,373,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Orthopediatrics in the 2nd quarter worth approximately $2,055,000. 50.52% of the stock is currently owned by institutional investors.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Featured Article: How does the Beige Book influence monetary policy?
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.